



## Minutes

**Date** Wednesday, 02/09/2020

**Time** 08.30am

**To** Committee Members

**At** Virtual via Microsoft Teams

**Subject** AWERB 3Rs Committee

**In Attendance:**

**Apologies:**

### 1. Minutes

The previous minutes were approved

### 2. Matters Arising

### 3. Retrospective Reviews

The committee discussed the following:

- **Testing of novel compounds**
- Section 3.6: It is stated the licence was not “fit for purpose”. The committee would like a more detailed explanation.
- Section 3.2 and 3.7: are empty. The committee would like more information about why it is impossible to reduce the number of animals or refine the methods
- **Development and evaluation of imaging agents in rodent models of neurodegeneration**
- Section 2.7: The committee is aware of the closure of Phenomics facility. However, this closure was planned and was not precipitated because of COVID-19
- Section 3.1: Using tissue from a previously killed animal is not considered a replacement. This information would fit better into the reduction section. The committee would also like to be provided with some figures. How many animals were not used because tissue was obtained from King’s College brain banks?
- Section 3.2: Please can you provide an estimate of animal reduction thanks to the imaging methods used.
- Section 3.7: The committee is asking for this section to be revised in depth regarding typing errors and grammar mistakes. Please can the statement be clarified that no mortality was observed. Was there any mortality during the course of the previous licence and if yes what has been modified to prevent this.



**4. Retrospective Assessments**

(a) None

**5. Project Licence Applications**

(a) None

**6. Severe Severity licence reviews**

- **██████████ - Promoting proliferation in non-regenerative tissues**

The committee recommends that any reference to ██████████ by name be removed from the application and replaced with 'a biostatistician'. ██████████ tenure with UBS has ended so any further discussion with him regarding statistics would need to be discussed with him. The committee does commend you on the use of a biostatistician to help design and plan your experiments.

- **██████████ – Roles for genomic instability in cancer and ageing**

Protocol 8: The scientific endpoints of this protocol are unclear and hence the harm done to the animal is difficult to understand. This is also reflected in the statistical analysis section with incoherence regarding group size. The committee felt that if the group is uncertain about the harm and the scientific outcomes it would be beneficial to include pilot studies with early humane endpoint. The data generated by those pilot studies should then provide more accurate information to calculate appropriate sample size and establish realistic humane and scientific endpoints.

**7. Standard Condition 18 reports**

**8. 3Rs information/reports**

**9. Feedback from previous Retrospective Reviews\***

None

**10. Minutes of AOC meeting\***

None

**11. Minutes of AWERB Standing meeting\***

None

**12. Any Other Business**

**Date of next meeting:** Wednesday 3rd June 2020

**\*Items for information only unless un-starred by committee member**